Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Raxibacumab - Emergent BioSolutions

Drug Profile

Raxibacumab - Emergent BioSolutions

Alternative Names: ABthrax; PAmAb

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Human Genome Sciences
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anthrax

Most Recent Events

  • 03 Oct 2017 Emergent BioSolutions acquires raxibacumab from GlaxoSmithKline
  • 19 Jul 2017 Emergent BioSolutions enters into an agreement with GlaxoSmithKline to acquire raxibacumab
  • 01 Aug 2014 GlaxoSmithKline plans a phase IV post-exposure study for Anthrax prevention and treatment in USA (NCT02177721)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top